China
Africa
Explore chapters and articles related to this topic
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
From January 1990 to June 2008, in Leuven, Belgium, 315 patients were diagnosed with contact allergy to/allergic contact dermatitis from corticosteroids (CSs) from routine patch testing with a baseline series including tixocortol pivalate, budesonide, hydrocortisone butyrate and prednisone caproate, patch testing with patients’ own CS preparations, and testing those with proven contact allergy to a corticosteroid or strongly suspected of CS allergy later with a series of 66 CSs, including two sex hormones (progesterone and testosterone). 71% of the patients had relevant reactions, but these were not specified. In this group of 315 CS allergic patients, 10 had positive patch tests to fluprednidene acetate 0.1% alc. (2). It is unknown how many of these reactions were caused by the use of a pharmaceutical product containing fluprednidene acetate and how many were cross-reactions to other corticosteroids (probably all).
A systematic review of evidence based treatments for lichen simplex chronicus
Published in Journal of Dermatological Treatment, 2021
Michelle C. Juarez, Shawn G. Kwatra
Two studies reported on the efficacy of halobetasol propionate in reducing disease severity in patients with LSC, noting a significant reduction in pruritus, erythema, scaling, and lichenification in treated patients compared to controls (5,6). In two separate double-blind multicenter RCTs comparing the efficacy of halobetasol propionate to diflucortolone valerate and clobetasol 17-propionate respectively, halobetasol had higher success rates and onset of action compared to diflucortolone, and higher healing rates than clobetasol, though these results were not statistically significant (7,8). In a double-blind RCT to compare the efficacy of once daily application of fluprednidene-21-acetate to thrice daily application of betamethasone 17-valerate (9), no significant differences in the reduction of symptomatology scores were noted in either group after 2 weeks of treatment (mean change in score 5.3 for fluprednylidene-21-acetate and 3.8 for betamethasone p =.17) suggesting that fluprednylidene applied once daily was as effective as thrice daily application of betamethasone, allowing for smaller quantities of a potent steroids to be applied with potentially fewer side effects.